Citius Pharmaceuticals, INC 8-K filings

Citius Oncology announces a significant 78% quarter-over-quarter increase in new institutional accounts ordering LYMPHIR, alongside near-universal payer coverage and expanding formulary approvals.

Citius Oncology announced positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies, showing durable responses and manageable tolerability.

Citius Pharmaceuticals reports $5.6 million in LYMPHIR net revenue for the first half of fiscal 2026 and secures $41.5 million in total new financing.

Citius Pharmaceuticals and its subsidiary, Citius Oncology, have amended a $3.8M promissory note to align with new senior debt obligations and introduce a conversion feature.

Citius Oncology announces the initial shipment of its oncology drug LYMPHIR to Europe, expanding international patient access through regional distribution partners and Named Patient Programs.

Citius Pharmaceuticals has raised $5 million in gross proceeds through a registered direct offering and concurrent private placement to support the commercialization of LYMPHIR.

Citius Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on April 6, 2026, where directors were elected and an independent auditor was ratified.

Citius Oncology, a Citius Pharma subsidiary, announced encouraging early commercial indicators for its CTCL treatment LYMPHIR, including broad institutional uptake and payer coverage.

Citius Oncology announced positive topline Phase 1 safety and efficacy results for LYMPHIR (E7777) administered prior to CAR-T therapy in high-risk DLBCL patients.

Citius Pharmaceuticals, Inc. announced its first revenue of $3.9 million from LYMPHIR sales but received a Nasdaq delisting notice for its common stock trading below $1.00 per share.

Citius Pharmaceuticals announced the U.S. launch of its cancer immunotherapy LYMPHIR and reported fiscal year 2025 financial results, including a net loss of $39.7 million.

Citius Oncology, a subsidiary of Citius Pharmaceuticals, announced the commercial launch of LYMPHIR for relapsed or refractory Stage I-III cutaneous T-cell lymphoma in the U.S.

Citius Pharmaceuticals, Inc. announces FDA approval and Q4 2025 commercialization plans for LYMPHIR, alongside positive Phase 3 results for Mino-Lok.

Citius Pharmaceuticals Inc. completed a registered direct offering, raising approximately $6.0 million in gross proceeds to fund LYMPHIR commercialization and pipeline development.

Citius Pharmaceuticals reports reduced Q3 2025 net loss and significant capital raises, positioning for the Q4 2025 U.S. launch of its FDA-approved drug, LYMPHIR.

Citius Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Stock Market.

Citius Pharmaceuticals Inc. has successfully closed a registered direct offering, raising approximately $6 million in gross proceeds, with potential for an additional $9.8 million from warrant exercises, to support the commercial launch of its FDA-approved drug LYMPHIR and advance its pipeline.

Citius Pharmaceuticals, Inc. announced a significant increase in its authorized common and total shares, approved by stockholders, alongside the redemption of its Series A Preferred Stock.

Citius Pharmaceuticals, Inc. has entered into a material definitive agreement for a $1 million unsecured promissory note with PAGODA RESOURCES, INC., bearing a 15.00% annual interest rate and personally guaranteed by its Chairman and CEO, Leonard Mazur.

Citius Pharmaceuticals, Inc. has received a Nasdaq delisting notice due to its common stock trading below the $1.00 minimum bid price requirement and plans to appeal the determination by June 5, 2025.

Citius Pharmaceuticals announced its fiscal second quarter 2025 financial results, highlighting progress towards the planned launch of LYMPHIR and ongoing efforts to secure financing.

Citius Pharmaceuticals issued a single share of Series A Preferred Stock to its CEO, Leonard Mazur, for $100 to ensure the approval of a proposal to increase the authorized number of common shares from 16,000,000 to 250,000,000.

Citius Oncology, a subsidiary of Citius Pharmaceuticals, has amended its license agreement with Eisai to establish a payment schedule for outstanding milestone and development costs related to LYMPHIR.

Citius Pharmaceuticals has entered into a definitive agreement for a $2 million registered direct offering of common stock and pre-funded warrants.

Citius Pharmaceuticals held its 2025 annual meeting of stockholders on March 10, 2025, where directors were elected, executive compensation was approved on an advisory basis, and the selection of an independent auditor was ratified, but a proposal to increase the authorized number of shares was not approved.

Citius Pharmaceuticals announced its fiscal first quarter 2025 financial results, highlighting progress in commercializing LYMPHIR and securing additional financing.

Citius Pharmaceuticals and its subsidiary Citius Oncology announced that LYMPHIR (denileukin diftitox-cxdl) has been assigned a unique, permanent J-code by the Centers for Medicare & Medicaid Services, effective April 1, 2025.

Citius Pharmaceuticals has finalized agreements for a $3 million registered direct offering of common stock and warrants, priced at-the-market under Nasdaq rules.

Citius Pharmaceuticals and its subsidiary Citius Oncology are making significant progress in preparing for the commercial launch of LYMPHIR, an immunotherapy for cutaneous T-cell lymphoma, planned for the first half of 2025.

Citius Pharmaceuticals announced its fiscal year 2024 results, marked by FDA approval of LYMPHIR and positive Phase 3 trial results for Mino-Lok, while also reporting a net loss of $39.4 million.